Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | JUN | P05412 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | VCP | P55072 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6247630 | 0.90 | TSHR (0.58) | TSHRNR3C1ALDH1A1JUNNFKB1 | |
| SCHEMBL28937646 | 0.82 | MAPT (0.63) | TSHRALDH1A1GAAKDM4EMAPT | |
| SCHEMBL3245649 | 0.81 | PIM1 (0.47) | TSHRNR3C1ALDH1A1GAAKDM4E | |
| SCHEMBL10425842 | 0.81 | TSHR (0.66) | TSHRNR3C1ALDH1A1JUNNFKB1 | |
| SCHEMBL26944947 | 0.81 | ALDH1A1 (0.46) | TSHRNR3C1ALDH1A1TNFSF11PTGS1 | |
| SCHEMBL987450 | 0.81 | ALDH1A1 (0.47) | TSHRNR3C1ALDH1A1TNFSF11PTGS1 | |
| SCHEMBL18660017 | 0.81 | GAA (0.56) | TSHRNR3C1ALDH1A1GAAKDM4E | |
| SCHEMBL2075457 | 0.81 | ALDH1A1 (0.51) | TSHRNR3C1ALDH1A1GAAKDM4E | |
| Hydroxyamine SCHEMBL4369811 | 0.80 | KDM4E (0.62) | TSHRNR3C1ALDH1A1GAAKDM4E | |
| SCHEMBL2438047 | 0.80 | KDM4E (0.67) | TSHRNR3C1ALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4552695-A2 | TYROSINE KINASES INHIBITORS AND USES THEREOF | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2025-05-14 | — | — | EP | disclosed |
| US-20250120967-A1 | TYROSINE KINASES INHIBITORS AND USES THEREOF | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2025-04-17 | — | — | US | disclosed |
| CN-112996784-B | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20220235064-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2022-07-28 | — | — | US | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| CN-114206883-A | Oxopyridine fused ring derivative and pharmaceutical composition comprising the same | 伟迈可生物有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-112996784-A | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021025407-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 웰마커바이오 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021025407-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 웰마커바이오 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| WO-2006117552-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| CN-1252054-C | Qinoline derivatives inhibiting effect of growth factors such as VEGF | ZENECA LTD (GB) | 2006-04-19 | — | — | CN | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| EP-0912182-A4 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO INC (US) | 1999-12-29 | — | — | EP | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| EP-0912182-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| WO-1998000144-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120967-A1 | TYROSINE KINASES INHIBITORS AND USES THEREOF | LCK, LTK, HIF1AN | TSHR 3238/4885NR3C1 3426/4885ALDH1A1 2912/4885 |
| US-20220235064-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ROS1, ROR1, RET | TSHR 546/4885NR3C1 162/4885ALDH1A1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.